Compare BridgeBio Pharma Inc (BBIO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ABRDN Physical Gold Shares ETF — how do they compare? BridgeBio Pharma Inc trades at $82.83 (market cap $16.46B), while ABRDN Physical Gold Shares ETF trades at $38.63. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SGOL | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $90.17 | $51.41 |
52-Week Low | $44.81 | $31.18 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SGOL is trading at $38.1, down 2.61% amid broader gold market weakness. The technical picture shows bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. Gold ETFs face headwinds from rising Treasury yields and Federal Reserve policy uncertainty, though central bank buying provides underlying support. Recent CPI data provided temporary relief but failed to sustain momentum.
The outlook remains cautious as gold faces competing forces - supportive central bank demand versus restrictive monetary policy. Near-term direction hinges on Fed policy clarity and inflation trends, with technical resistance at $39-$40 levels posing immediate challenges for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
